Switching to sirolimus versus continuing an mTOR inhibitor for the prevention of rejection in renal transplant recipients

Trial Profile

Switching to sirolimus versus continuing an mTOR inhibitor for the prevention of rejection in renal transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Sep 2012

At a glance

  • Drugs Sirolimus (Primary) ; Azathioprine; Ciclosporin; Immunosuppressants; Mycophenolate mofetil; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top